Member Info for MrJonesSmith

Hi Scully

I was doing dummy trades at the time , I was offered 4.11p to sell my shares and to buy it was 4.25p.

Certainly moves quickly on little volume . Good Luck

The First Trade today at 4.25 pence was a buy.

Current Shareholder Information - Taken from Prospectus

523 Million in total .

There is only 88 million shares available in the free float.

Panetta Partners
251,087,103 47.95%

Beaufort Nominees
Limited (including the
shareholding of Rosy
Mining Limited)* 119,997,937 22.91%

Regent Mercantile
Holdings Limited 32,672,906 6.24%

James Mellon 31,912,948 6.09%

Firstly , thanks for your input on the board its most appreciated.

It still amazes me that even after two suspensions that people would still invest in AIQ at 28p

Will be interesting to see how this plays out , who knows we could get to 10 p or 20p with so little stock available.

Can't personally see this going back to 2p , the market absorbed a lot of stock on Friday ,

Time will tell and anything could happen it's Aim after all . Good luck with your investments. I;m in with a small punt .

Under Directors Deals it has Willy J Simon holding 307k worth of shares.

Does anyone know if this is an existing holding of if he did purchase them on the 17 of July , can't find any RNS to back it up as a new puchase.

Thanks

NT to buy via Halifax

AND 1 BILLION DOLLARS OF ADDITIONAL SALES

PureTech Health will receive up to $36 million, including upfront payments, research support, and early preclinical milestones. PureTech Health will be eligible to potentially receive development milestone payments of over $1 billion and additional sales milestones and royalties for an undisclosed number of products.

Interesting to see Jim Mellon has around 32 million shares .

Taken from company website

James Mellon

31,912,948

6.09%

and it's not even 12 O'clock. Amazing volume

Currently 310 million shares available .

150 million of those shares already taken up check share holder information on company website and nearly 50 million of them have been traded thus far.

Can't believe this opened up at 1.60.

over 11 million shares traded within the first 30 minutes , brillant RNS.

Aim Securities Not In Public Hands
Last updated 5 June 2018, 30.8% of the company’s issued ordinary shares were not in public hands.

Significant Shareholders
Shareholder
Number of
ordinary shares of 0.1p each
Percentage of
issued share
capital
JIM NOMINEES LIMITED
17,560,305
11.93%
INTERACTIVE INVESTOR SERVICES NOMINEES LIMITED (1)
14,630,833
9.94%
BARCLAYS DIRECT NOMINEES LIMITED
14,032,294
9.53%
HSDL NOMINEES LIMITED
10,926,350
7.42%
HARGREAVES LANSDOWN (NOMINEES) LIMITED (1)
6,911,591
4.7%
HARGREAVES LANSDOWN (NOMINEES) LIMITED (2)
6,911,591
4.7%
HARGREAVES LANSDOWN (NOMINEES) LIMITED (3)
6,155,952
4.18%
MATT LOFGRAN
5,975,976
4.06%
HSBC CLIENT HOLDINGS NOMINEE (UK) LIMITED
5,899,923
4.01%
SHARE NOMINEES LTD
5,080,272
3.45%
INTERACTIVE INVESTOR SERVICES NOMINEES LIMITED
5,079,931
3.45%
As at 5 June 2018.

Aim Securities Not In Public Hands
Last updated 5 June 2018, 30.8% of the company’s issued ordinary shares were not in public hands.

Significant Shareholders
Shareholder
Number of
ordinary shares of 0.1p each
Percentage of
issued share
capital
JIM NOMINEES LIMITED
17,560,305
11.93%
INTERACTIVE INVESTOR SERVICES NOMINEES LIMITED (1)
14,630,833
9.94%
BARCLAYS DIRECT NOMINEES LIMITED
14,032,294
9.53%
HSDL NOMINEES LIMITED
10,926,350
7.42%
HARGREAVES LANSDOWN (NOMINEES) LIMITED (1)
6,911,591
4.7%
HARGREAVES LANSDOWN (NOMINEES) LIMITED (2)
6,911,591
4.7%
HARGREAVES LANSDOWN (NOMINEES) LIMITED (3)
6,155,952
4.18%
MATT LOFGRAN
5,975,976
4.06%
HSBC CLIENT HOLDINGS NOMINEE (UK) LIMITED
5,899,923
4.01%
SHARE NOMINEES LTD
5,080,272
3.45%
INTERACTIVE INVESTOR SERVICES NOMINEES LIMITED
5,079,931
3.45%
As at 5 June 2018.

Hopefully If we can break through 12p ,then off to the races.

however this AIM.

Well Done to the long Term Holders who kept the faith you deserve it..

Fantastic RNS .

0.90 on the Bid right now

looking good

Volume slightly picking up 41.25 to buy.

Summit Therapeutics receives grant to further its development of a treatment for gonorrhoea
12:37 10 Jul 2018
Summit has identified a series of new mechanism antibiotic compounds that have shown high potency against a range of Neisseria gonorrhoea strains, including those that were multi-drug resistant.
Couple making love
pdf icon Download Summit Therapeutics PLC
Capital Network report here
Gonorrhoea is a sexually transmitted infection
Drug developer Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) has been awarded a US$4.5mln grant from CARB-X to develop its antibiotic compounds for gonorrhoea.

CARB-X is a public-private partnership devoted to accelerating early antibiotic research and development.

READ Summit Therapeutics unveils second series of compounds that could kill gonorrhoea bacteria
Summit will receive an initial US$2.0mln in funding from CARB-X that will in part fund the selection of a preclinical candidate from Summit’s lead gonorrhoea series. The selection of a lead candidate is expected in the second half of 2018.

The remaining US$2.5mln is split into two option segments, which may be exercised by CARB-X upon the achievement of certain development milestones. If exercised in full, this funding could support the development of the selected gonorrhoea candidate through the end of a Phase 1 clinical trial.

“This CARB-X collaboration and funding is important to us as we aim to pioneer a new era in antibiotic innovation and allows us to accelerate the development of our first series of new mechanism of action gonorrhoea compounds,” said Glyn Edwards, the chief executive officer of Summit.

“The award is a testament to the promise of our gonorrhoea programme, and the discovery capability of our proprietary genetics-based platform,” he added.

Resistance to antibiotics used to treat the STI is growing​
The World Health Organization (WHO) estimates that there are around 78mln new cases of gonorrhoea each year and the number of antibiotics that can combat Neisseria gonorrhoeae has now declined to just one treatment recommended by the Centers for Disease Control and Prevention (CDC).

The WHO ranks as “high” the priority of research & development investment into the search for antibiotics that are effective against Neisseria gonorrhoeae.

“Drug-resistant gonorrhoea is an urgent and growing public health problem around the world, affecting the health and quality of life of millions of people,” said Kevin Outterson, the executive director of CARB-X.

“The world urgently needs new antibiotics, like those that Summit is developing, and other life-saving products to protect us from drug-resistant bacteria. The projects in the Powered by CARB-X portfolio are in the early stages of development, but if successful, they offer tremendous potential in the fight against superbugs,” he added.

Shares in Summit, which plummeted earlier this month when the company’s treatment for Duchenne’s muscular dystrophy failed a clini

The RNS was released at 12.00 today , a lot of investor have missed it as it not showing on LSE.

Hopefully the share price will improve from here.